)
Edge23 Jan 2026
Death, Taxes, and Garbage: The Story of WM
How Waste Management turned garbage into one of America's most stable business models through landfills, regulation, and nationwide scale.
Alto Neuroscience
Alto Neuroscience (ANRO) investor relations material
Alto Neuroscience Corporate presentation summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Corporate presentation summary12 Jan, 2026
Mission and strategic approach
Aims to redefine psychiatry by developing personalized, neurobiology-driven medicines for mental health disorders.
Focuses on precision medicine for CNS, using biomarkers to identify responsive patient populations and improve clinical outcomes.
Addresses unmet needs in mental health, targeting depression, schizophrenia, and bipolar disorder with novel mechanisms.
Utilizes a biomarker platform to segment patients and guide drug development, reducing trial-and-error in treatment.
Leverages proprietary cognitive and EEG-based biomarkers for patient selection and monitoring.
Pipeline and clinical programs
ALTO-207 (TRD): Combines D3/D2 agonist and 5-HT3 antagonist, showing robust antidepressant effects and improved tolerability; pivotal Phase 2b and Phase 3 trials planned for 2026–2027.
ALTO-300 (MDD): Multi-modal antidepressant (agomelatine) with EEG biomarker-guided patient selection; Phase 2b ongoing, topline data expected mid-2026.
ALTO-100 (Bipolar Depression): Enhances hippocampal neuroplasticity, with Phase 2b trial in biomarker-positive patients; topline data expected 2H 2026.
ALTO-101 (CIAS): Novel PDE4 inhibitor for cognitive impairment in schizophrenia, showing pro-cognitive effects and ongoing POC study; data expected 1Q 2026.
ALTO-203 (MDD): H3 inverse agonist with effects on multiple neurotransmitter systems, showing positive pharmacodynamic effects in early studies.
Clinical and commercial highlights
Over 800 patients dosed across studies, with more than 25 million patient impact opportunity.
Multiple mid- to late-stage data readouts expected in the next two years.
Cash runway projected into 2028, with $184.2 million as of October 2025.
Strong IP portfolio and commercial strategies to mitigate generic substitution risks.
Recent analogs in psychiatry support the combination approach and novel mechanisms, indicating blockbuster potential for lead candidates.
Mitigate ALTO-207 generic substitution risk?
Confirm ALTO-300 EEG biomarker specificity.
Rationale for ALTO-100 bipolar depression focus?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Alto Neuroscience earnings date
Q4 202520 Mar, 2026
Alto Neuroscience
Next Alto Neuroscience earnings date
Q4 202520 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Alto Neuroscience Inc. is a clinical-stage biopharmaceutical company based in the United States, focusing on developing precision medicine for psychiatric conditions. The company leverages AI-derived brain biomarkers to tailor psychiatric drug development to individual patients, aiming to improve treatment effectiveness for mental health issues. Their approach integrates detailed patient-specific data to optimize the drug development process. Alto Neuroscience has a range of products in clinical trials targeting conditions such as major depressive disorder and post-traumatic stress disorder. The company is headquartered in Los Altos, California, and its shares are listed on the NYSE under the ticker ANRO.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage